Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
The singer-songwriter gained recognition from the Recording Academy in the early 1990s, winning the Grammy for Best New ...
AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...
AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the progression of Parkinson’s disease motor symptoms in a Phase III trial. The University College London (UCL) in the UK ...